RMX-GPC3

N/A

Report date: 2026/04/23 20:00:25

NME

Base Information

Drug NameRMX-GPC3

Drug Alias NameRMX-GPC3212-Pb-RMV-GPC3-VH

ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lead > 212Pb +[4]

Mechanisms of ActionEmission-computed tomography enhancersIonising radiation emittersPositron-emission tomography enhancers +[4]

TargetsGlypican-3

Therapy Area/IndicationsSolid tumoursCarcinoma, Pancreatic DuctalGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRadiomedix Inc

China Registration ClassN/A

Develop Information

Active CompaniesRadiomedix Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Pancreatic DuctalGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A